Skip to content
Screener

Opus Genetics IRD Q1 2026 earnings

Reported May 12, 2026 · Before market open

Revenue$2.2MMiss by $771.1K
EPS-$0.75Miss by $0.59
Revenue estimate$2.9M
EPS estimate-$0.16

Next report

Nov 11, 2026 (in 2 months)
Revenue estimate$1.5M
EPS estimate-$0.14

Financials

Q1 2026

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M—
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$323.73M+633%
Enterprise value$264.97M—
P/S27×+23.8×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Current ratio7.1×+5.2×

FAQ

When did Opus Genetics report Q1 2026 earnings?
Opus Genetics (IRD) reported Q1 2026 earnings on May 12, 2026 before market open.
What were Opus Genetics's Q1 2026 revenue and EPS?
Opus Genetics reported revenue of $2.2M and eps of $-0.75 for Q1 2026.
Did Opus Genetics beat estimates in Q1 2026?
Revenue missed the consensus estimate of $2.9M by $771.1K. EPS missed the consensus estimate of $-0.16 by $0.59.
How did Opus Genetics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 50.6% from $4.4M a year earlier and eps declined 134.4% from $-0.32.
Where can I find Opus Genetics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-033856) and the 10-Q periodic report (0001628280-26-034084) directly on SEC EDGAR. The filing index links above go to sec.gov.